AZD9291 is an irreversible, mutant specific EGFR tyrosine kinase inhibitor. It is effective in pre-clinical tumor models and clinical trials in patients with TKI sensitizing and T790M resistant tumors. It is generally well tolerated. Activating mutations within the epidermal growth factor receptor (EGFR) mutations are present in approximately 20% of all lung adenocarcinomas. EGFR -mutant cancers are dependent on EGFR signaling for growth and survival, making inhibition of EGFR an attractive therapeutic target.
NCG 275215 E